Skip to main content

Adverum Biotechnologies, Inc.

ADVMDelisted Dec 9, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001501756

Adverum Biotechnologies, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 10, 2025; 50 institutions reported holding it in 13F filings for Q3 2025, worth $63.8M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
50
Q3 2025, −9 vs. previous quarter
13F value
$63.8M
Reported value at the end of Q3 2025
Superinvestors holding
0
At the end of Q3 2025

From SEC filings, in USD.

Revenue, FY2024
$1.00M
−72.2% year over year
Net income, FY2024
-$130.9M
No comparable prior period
Free cash flow, FY2024
-$92.8M
No comparable prior period
Revenue, Q3 FY2025
$0
−100.0% year over year

Revenue flow, FY2024

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2024: $130.9M (13092.7% of revenue).

Short interest

See short data

From FINRA, settlement date Nov 28, 2025.

Short interest
435.8K
Shares sold short
Change
−375.6K
−46.3% vs. previous
Days to cover
1.02
At average daily volume

Superinvestors holding ADVM, Q3 2025

Go to the superinvestors tab

No superinvestor reported holding ADVM at the end of Q3 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by Adverum Biotechnologies, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 8, 2025 (view filing)Dec 53 daysSoparkar PeterCHIEF OPERATING OFFICERPPurchase+50.0K$4.22+$211.0K+165.6%80.2K after
Dec 8, 2025 (view filing)Dec 5-83 daysFischer LaurentCEO, PRESIDENT AND DIRECTORPPurchase+128.7K$4.30+$553.9K+176.8%201.5K after2 lots
Dec 5, 2025 (view filing)Dec 41 dayLeonard Braden Michael10% OwnerSSale−524.6K$4.19−$2.20M−21.1%1.96M after
Dec 3, 2025 (view filing)Dec 1-32 daysLeonard Braden Michael10% OwnerSSale−574.9K$4.19−$2.41M−19.1%2.43M after3 lots
May 16, 2025 (view filing)May 151 daySoparkar PeterCHIEF OPERATING OFFICERSSale−2.96K$2.00−$5.92K−7.0%39.2K after
May 16, 2025 (view filing)May 151 daySeyedkazemi SetarehCHIEF DEVELOPMENT OFFICERSSale−924$2.00−$1.85K−6.3%13.8K after
May 16, 2025 (view filing)May 151 dayFischer LaurentCEO, PRESIDENT AND DIRECTORSSale−9.13K$2.00−$18.3K−9.4%87.5K after
Apr 28, 2025 (view filing)Mar 26-2733 daysLeonard Braden Michael10% OwnerPPurchase+37.0K$5.11+$189.0K+35.3%141.8K afterAmended2 lotsDuplicate filing
Apr 28, 2025 (view filing)Mar 26-2733 daysLateLeonard Braden Michael10% OwnerPPurchase+37.0K$5.11+$189.0K+35.3%141.8K after2 lots
Apr 24, 2025 (view filing)Apr 222 daysLeonard Braden Michael10% OwnerPPurchase+300.0K$3.00+$900.0K+10.9%3.06M after

Top 10 13F holders, Q3 2025

See all 50 holders

The largest institutional positions in Adverum Biotechnologies, Inc. at the end of Q3 2025; share changes are against Q2 2025.

Institutions holding ADVM in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
BML Capital Management, LLC3,057,526$13.9M12.74%00.0%Unchanged
Principia Wealth Advisory, LLC2,077,946$9.41M6.72%+48,830+2.4%Added
Frazier Life Sciences Management, L.P.2,077,431$9.41M0.28%+1,008,187+94.3%Added
TCG Crossover Management, LLC1,668,174$7.56M0.37%−128,308−7.1%Reduced
Vanguard Group Inc872,041$3.95M0.00%−11,896−1.3%Reduced
5AM Venture Management, LLC541,666$2.45M0.90%00.0%Unchanged
Versant Venture Management, LLC506,821$2.30M1.08%00.0%Unchanged
Goldman Sachs Group Inc402,581$1.82M0.00%−94,706−19.0%Reduced
Renaissance Technologies LLC363,496$1.65M0.00%−207,173−36.3%Reduced
Pale Fire Capital SE363,282$1.65M0.18%+4,558+1.3%Added

Holders of 5% or more of ADVM

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Adverum Biotechnologies, Inc..

Largest holders of ADVM from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
TCG Crossover GP II, LLC13G/A8.90%1.87M shares–Feb 15, 20242 filingsMay 15, 2025SEC
Rush Ryan Bradford13G5.10%1.05M sharesNewDec 17, 20241 filingDec 17, 2024SEC